Carolina Urologic Research Center, Myrtle Beach, SC
Neal D. Shore , Andrew J. Armstrong , Russell Zelig Szmulewitz , Daniel Peter Petrylak , Jeffrey Holzbeierlein , Arnauld Villers , Arun Azad , Antonio Alcaraz , Boris Alekseev , Taro Iguchi , Francisco Gomez-Veiga , Brad Rosbrook , Ho-Jin Lee , Gabriel P. Haas , Arnulf Stenzl
Background: ENZA + ADT significantly reduced the risk of radiographic progression or death in men with mHSPC (NCT02677896). Here, we assess how pattern of metastatic spread impacts the efficacy of ENZA + ADT in patients enrolled in ARCHES. Methods: Patients with mHSPC were randomized 1:1 to ENZA (160 mg/day) + ADT or placebo (PBO) + ADT, stratified by disease volume and prior docetaxel treatment. The primary endpoint was radiographic progression-free survival (rPFS). Secondary endpoints included time to prostate-specific antigen (PSA) progression, time to first symptomatic skeletal event (SSE), time to castration resistance, and time to initiation of new antineoplastic therapy. Post hoc analyses were performed by pattern of metastatic spread at study entry. Results: Of the overall population with known metastases at screening (n=1146), the largest patient subgroups were those with bone metastases only (n=513) and those with bone and soft-tissue metastases only (n=351); there were fewer M0 patients or patients with soft-tissue metastases only (n=154) and patients with visceral ± bone metastases (n=128). ENZA + ADT reduced the risk of rPFS and other secondary endpoint measures versus PBO + ADT across all subgroups, with greater relative efficacy observed in patients without visceral metastases (Table). Conclusions: ENZA + ADT provides improvements in rPFS and other secondary endpoints versus PBO + ADT in patients with mHSPC regardless of pattern of metastatic spread, particularly in patients without visceral metastases. These results highlight the importance of patient/physician discussion regarding the use of ENZA in the treatment of mHSPC. Clinical trial information: NCT02677896.
Endpoint, HR (95% CI) | Bone only (n=268;b n=245c) | Bone and soft tissue only (n=164;b n=187c) | M0a or soft tissue only (n=74;b n=80c) | Visceral ± bone (n=64;b n=64c) |
---|---|---|---|---|
rPFS | 0.33 (0.22, 0.49) | 0.31 (0.21, 0.47) | 0.43 (0.16, 1.20) | 0.94 (0.51, 1.73) |
Time to PSA progression | 0.12 (0.07, 0.22) | 0.24 (0.15, 0.39) | 0.07 (0.01, 0.54) | 0.39 (0.17, 0.90) |
Time to first SSE | 0.51 (0.27, 0.96) | 0.45 (0.22, 0.92) | NE (0.00, NR) | 0.45 (0.11, 1.81) |
Time to castration resistance | 0.25 (0.17, 0.36) | 0.26 (0.18, 0.39) | 0.33 (0.13, 0.82) | 0.49 (0.26, 0.92) |
Time to new antineoplastic therapy | 0.31 (0.19, 0.49) | 0.16 (0.08, 0.33) | 0.31 (0.07, 1.52) | 0.68 (0.28, 1.61) |
aAssessed as M0 by independent central review after investigator assessment as M1 at study entry; bENZA + ADT; cPBO + ADT NE, not estimable; NR, not reached
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2021 Genitourinary Cancers Symposium
First Author: Arun Azad
2021 ASCO Annual Meeting
First Author: Andrew J. Armstrong
2022 ASCO Genitourinary Cancers Symposium
First Author: Andrew J. Armstrong